An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
An Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents Aged ≥12 to ≤17 Years at the Time of Study Inclusion With Active Moderate to Severe Hidradenitis Suppurativa
Sponsor: MoonLake Immunotherapeutics AG
Listed as NCT06768671, this PHASE3 trial focuses on Hidradenitis Suppurativa and remains actively recruiting participants. Sponsored by MoonLake Immunotherapeutics AG, it has been updated 4 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
4 versions recorded-
Jan 2026 — Present [monthly]
Recruiting PHASE3
-
Oct 2025 — Jan 2026 [monthly]
Recruiting PHASE3
-
May 2025 — Oct 2025 [monthly]
Recruiting PHASE3
-
Feb 2025 — May 2025 [monthly]
Recruiting PHASE3
First recorded
Dec 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MoonLake Immunotherapeutics AG
For direct contact, visit the study record on ClinicalTrials.gov .